3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
22
Cisplatin
17
Surveys and Questionnaires
9
Radiotherapy
8
Carboplatin
8
Radiotherapy, Intensity-Modulated
7
Cetuximab
7
Paclitaxel
6
Nivolumab
6
Drug Therapy
6
Radiation
4
Fluorouracil
4
Taxes
3
Docetaxel
3
selpercatinib
2
dostarlimab
2
Yoga
2
Surgical Procedures, Operative
2
Standard of Care
2
Radiosurgery
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Chemoradiotherapy
2
Blood Specimen Collection
2
ALX148
2
veliparib
1
tisotumab vedotin
1
tislelizumab
1
palbociclib
1
osimertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Head and Neck Neoplasms
×
tisotumab vedotin
×
Clear all
NCT03485209
2026-04-20
innovaTV 207
Seagen Inc.
Phase 2
Active not recruiting
350 enrolled